Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830417 | 0.90 | OPRM1 (0.38) | OPRD1OPRM1CHRM2CHRM4OPRK1 | |
| SCHEMBL5830249 | 0.85 | OPRM1 (0.50) | OPRD1OPRM1CHRM2OPRK1MEN1 | |
| SCHEMBL5830426 | 0.83 | OPRM1 (0.46) | OPRD1OPRM1CHRM2OPRK1MEN1 | |
| SCHEMBL5879367 | 0.80 | OPRD1 (0.43) | OPRD1OPRM1CHRM4OPRK1 | |
| SCHEMBL5490000 | 0.77 | OPRD1 (0.62) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879402 | 0.77 | OPRD1 (0.59) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5630624 | 0.76 | OPRD1 (0.62) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5630813 | 0.75 | OPRD1 (0.64) | OPRD1OPRM1CHRM2OPRK1CHRM3 | |
| SCHEMBL5879308 | 0.75 | OPRD1 (0.54) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5830266 | 0.74 | OPRD1 (0.62) | OPRD1OPRM1CHRM2OPRK1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7008952-B2 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20040142966-A1 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142966-A1 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | HTR2C, HTR1D, HTR1A | OPRD1 5/4885OPRM1 17/4885CHRM2 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.